JAMA Dermatology

Arthritis & Rheumatism

Psoriatic arthritis: types, causes, symptoms & treatments

Most people have heard of osteoarthritis and rheumatoid arthritis. But for some, psoriatic arthritis is the new kid on the block. Here's what you need to know about psoriatic arthritis, including symptoms, types and treatments.

Diseases, Conditions, Syndromes

Age, race impact atherosclerotic risk with psoriasis

(HealthDay)—Some subgroups of patients with psoriasis are at greater risk for atherosclerotic cardiovascular disease (ASCVD), according to a research letter published online Feb. 20 in JAMA Dermatology.

Diseases, Conditions, Syndromes

Vitiligo, alopecia areata may up atopic dermatitis risk

(HealthDay)—The prevalence of atopic dermatitis (AD) is higher among patients with vitiligo or alopecia areata (AA), according to research published online Dec. 3 in JAMA Dermatology.

Diseases, Conditions, Syndromes

Study: Some biologic treatments for psoriasis may be safer for patients

A common chronic skin condition affecting 125 million people worldwide, psoriasis is an autoimmune disease, a class of disorders in which the immune system attacks the body's own healthy cells. In recent years, new medications—known ...

Oncology & Cancer

Overall survival worse with multiple primary melanomas

(HealthDay)—Patients with multiple primary melanomas have worse overall survival than those with a single primary melanoma, according to a study published online June 26 in JAMA Dermatology.

Medications

New options for treating eczema

Patients with severe eczema who were treated with the drug dupilumab experienced a reduction in symptoms and improved quality of life, according to a meta-analysis of several clinical trials published in JAMA Dermatology.

Medications

Tackling skin inflammation with vitamin D

High-dose oral vitamin D reduced skin inflammation and increased immunoprotection in patients with chemical-induced skin rashes, according to findings from a recent Northwestern Medicine clinical trial published in JCI Insight.

Medications

Living review compares treatments for atopic dermatitis

Abrocitinib, 200 mg daily, and upadacitinib, 30 mg daily, seem to be slightly better than dupilumab for atopic dermatitis, according to a living review published online March 16 in JAMA Dermatology.

page 7 from 37